BF-200 ALA (Ameluz®)

About Biofrontera

Biofrontera Inc. is a commercial-stage biopharma company with a mission to become a leading U.S. specialty dermatology firm by providing innovative, high-quality treatment options. Its core achievements include the successful U.S. commercialization of two FDA-approved products, Ameluz® and Xepi®, and the development of a proprietary nanoemulsion technology platform. The company's strategy is to deepen its expertise in photodynamic therapy, expand its portfolio through label extensions and new indications for its core assets, and build a consultative commercial model to serve dermatology healthcare providers.

About Biofrontera

Biofrontera Inc. is a commercial-stage biopharma company with a mission to become a leading U.S. specialty dermatology firm by providing innovative, high-quality treatment options. Its core achievements include the successful U.S. commercialization of two FDA-approved products, Ameluz® and Xepi®, and the development of a proprietary nanoemulsion technology platform. The company's strategy is to deepen its expertise in photodynamic therapy, expand its portfolio through label extensions and new indications for its core assets, and build a consultative commercial model to serve dermatology healthcare providers.

About Biofrontera

Biofrontera Inc. is a commercial-stage biopharma company with a mission to become a leading U.S. specialty dermatology firm by providing innovative, high-quality treatment options. Its core achievements include the successful U.S. commercialization of two FDA-approved products, Ameluz® and Xepi®, and the development of a proprietary nanoemulsion technology platform. The company's strategy is to deepen its expertise in photodynamic therapy, expand its portfolio through label extensions and new indications for its core assets, and build a consultative commercial model to serve dermatology healthcare providers.

About Biofrontera

Biofrontera Inc. is a commercial-stage biopharma company with a mission to become a leading U.S. specialty dermatology firm by providing innovative, high-quality treatment options. Its core achievements include the successful U.S. commercialization of two FDA-approved products, Ameluz® and Xepi®, and the development of a proprietary nanoemulsion technology platform. The company's strategy is to deepen its expertise in photodynamic therapy, expand its portfolio through label extensions and new indications for its core assets, and build a consultative commercial model to serve dermatology healthcare providers.

About Biofrontera

Biofrontera Inc. is a commercial-stage biopharma company with a mission to become a leading U.S. specialty dermatology firm by providing innovative, high-quality treatment options. Its core achievements include the successful U.S. commercialization of two FDA-approved products, Ameluz® and Xepi®, and the development of a proprietary nanoemulsion technology platform. The company's strategy is to deepen its expertise in photodynamic therapy, expand its portfolio through label extensions and new indications for its core assets, and build a consultative commercial model to serve dermatology healthcare providers.

About Biofrontera

Biofrontera Inc. is a commercial-stage biopharma company with a mission to become a leading U.S. specialty dermatology firm by providing innovative, high-quality treatment options. Its core achievements include the successful U.S. commercialization of two FDA-approved products, Ameluz® and Xepi®, and the development of a proprietary nanoemulsion technology platform. The company's strategy is to deepen its expertise in photodynamic therapy, expand its portfolio through label extensions and new indications for its core assets, and build a consultative commercial model to serve dermatology healthcare providers.

About Biofrontera

Biofrontera Inc. is a commercial-stage biopharma company with a mission to become a leading U.S. specialty dermatology firm by providing innovative, high-quality treatment options. Its core achievements include the successful U.S. commercialization of two FDA-approved products, Ameluz® and Xepi®, and the development of a proprietary nanoemulsion technology platform. The company's strategy is to deepen its expertise in photodynamic therapy, expand its portfolio through label extensions and new indications for its core assets, and build a consultative commercial model to serve dermatology healthcare providers.

Therapeutic Areas